Health Trials

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

ConditionsLow-grade NMIBCFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationFGFR3 Gene Fusions
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorTyra Biosciences, Inc

About this trial

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Eligibility criteria

Qualifiers

Participants age 18 and over of informed consent and willing and able to comply with all requires study procedures

Able to understand and given written informed consent

Ta low grade

T1 low grade

Disqualifiers

Current or previous history of muscle invasive bladder cancer

Current or previous history of lymph node positive and/or metastatic bladder cancer

Evidence of pure squamous cell carcinoma, pure adenocarcinoma or pure undifferentiated carcinoma of the bladder

Currently receiving systemic cancer therapy (cytotoxic, immunotherapy, targeted)

Trial design

Treatments tested in this trial

  • TYRA-300 60mg
  • TYRA-300 50mg
  • TYRA-300 Dose TBD

Treatment groups

90 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Tyra Biosciences, Inc

Lead sponsor

Source ClinicalTrials.gov